It has drugs in development for ten diseases and two ongoing clinical trials, including ones for diabetic nerve injuries.

FORBES: Magazine Article

Serious adverse events also occurred more often in the niacin group, including new onset diabetes (9.1 vs. 7.3 percent), diabetic complications (11.1 vs. 7.5 percent), gastrointestinal problems (4.8 vs. 3.8 percent), and skin problems such as itching and rashes (0.7 vs. 0.4 percent).

FORBES: HPS2-THRIVE: A 'Disappointing But Clear' Result